Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Host immunology and rational immunotherapy for carbapenem-resistant Klebsiella pneumoniae infection
Naoki Iwanaga, Ivy Sandquist, Alanna Wanek, Janet McCombs, Kejing Song, Jay K. Kolls
Naoki Iwanaga, Ivy Sandquist, Alanna Wanek, Janet McCombs, Kejing Song, Jay K. Kolls
View: Text | PDF
Research Article Infectious disease Pulmonology

Host immunology and rational immunotherapy for carbapenem-resistant Klebsiella pneumoniae infection

  • Text
  • PDF
Abstract

Infections due to carbapenem-resistant Klebsiella pneumoniae have emerged as a global threat due to its widespread antimicrobial resistance. Transplant recipients and patients with hematologic malignancies have high mortality rate, suggesting host factors in susceptibility. We developed a model of pulmonary infection using ST258 strain C4, KPC-2 clone, which are predominant K. pneumoniae carbapenemase–producing (KPC-producing) bacteria, and demonstrated that Rag2–/– Il2rg–/– mice — but not WT C57BL/6 or Rag2–/– mice — were susceptible to this opportunistic infection. Using single cell RNA sequencing in infected Rag2–/– mice, we identified distinct clusters of Ifng+ NK cells and Il17a+, Il22+, and inducible T cell costimulatory molecule–positive (ICOS+) group 3 innate lymphoid cells (ILCs) that were critical for host resistance. As solid organ transplantation is a risk factor, we generated a more clinically relevant model using FK506 in WT C57BL/6 mice. We further demonstrated that immunotherapy with recombinant IL-22 treatment ameliorated the ST258 pulmonary infection in both FK506-treated WT mice and Rag2–/– Il2rg–/– mice via hepatic IL-22ra1 signaling. These data support the development of host-directed immunotherapy as an adjunct treatment to new antibiotics.

Authors

Naoki Iwanaga, Ivy Sandquist, Alanna Wanek, Janet McCombs, Kejing Song, Jay K. Kolls

×

Figure 9

IL-22:Fc–mediated bacteriostatic activity is partially dependent on complement produced by hepatocyte.

Options: View larger image (or click on image) Download as PowerPoint
IL-22:Fc–mediated bacteriostatic activity is partially dependent on comp...
(A and B) A total of 4 μg IL-22:Fc–treated serum for 24 hours in WT C57BL/6 mice augmented bacteriostatic activity against ST258 C4 (A), and the bacteriostatic effect proved to be heat labile by using heat-inactivated serum (B). (C) The bacteriostatic effect by IL-22:Fc treatment was diminished in C3–/– mice more than WT mice. Lastly, 4- to 8-week-old male Il22ra1fl/fl mice and Il22ra1ΔHEP mice were treated with 4 μg IL-22:Fc i.p. for 24 hours, and blood were collected. (D and E) IL-22:Fc–treated serum in Il22ra1fl/fl mice results in more deposition of C3 binding to ST258 C4 after coincubation with 1 × 105 CFU ST258 C4 in vitro, but the effect was abrogated in Il22ra1ΔHEP mice. Data are presented as mean ± SEM. Representative data are shown of 2 separate experiments. Significant differences are designated by using ANOVA followed by Tukey’s multiple comparisons test. †P < 0.05 (vs. IL-22:Fc–treated C3–/– mice), ****P < 0.0001 (vs. medium, WT, C3–/– mice). *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts